The cost and how to improve the affordability of insulin have been the subject of debate long before the celebration of the 100-year anniversary of its discovery began in 2021. While some have struggled to be optimistic, a new development involving a major corporate entity could signal a paradigm shift in the uphill battle.
In late June 2021, Walmart announced it would be partnering with Novo Nordisk to launch the first-ever private brand analog insulin. Marketed under the private label ReliOn NovoLog Insulin, a press release from Walmart states the insulin aspart injection could help patients save 58-75% off the cash price of branded insulin products. With availability expected in Walmart and Sam’s Club pharmacies by mid-July, the insulin will be available in both vials and pens.
How this development could impact patients and clinicians is the subject of the first of 3 video segments in Endocrinology Network’s “Insulin for All? How Recent Developments Impact Insulin Affordability”.